

POLYMORPH OF A PHARMACEUTICAL

Technical Field

5 The present invention relates to novel crystalline polymorphs of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer), methods for their preparation, and pharmaceutical compositions comprising the novel crystalline polymorphs.

Background of the Invention

10 The antimicrobial agent 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) (hereinafter referred to as "Cefdinir") is a semi-synthetic oral antibiotic in the cephalosporin family. Cefdinir is active against a very wide spectrum of bacteria, including *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *E. coli*, *Klebsiella*, and
15 *Proteus mirabilis*. The preparation of this agent was first disclosed in U.S. Patent Serial No. 4,559,334, issued December 17, 1985, which is hereby incorporated by reference in its entirety.

A novel crystalline form of Cefdinir (originally referred to as "Crystal A", herein referred to as "Form I") was first disclosed in U.S. Patent Serial No. 4,935,507, issued June
20 19, 1990, which is hereby incorporated by reference in its entirety. While this polymorph does overcome several of the problems associated with the amorphous form, the formation of additional new polymorphs can provide further advantages such as increased stability.

It has now been unexpectedly discovered that Cefdinir can be prepared as a new crystalline polymorph which is termed Form II.

25

Brief Description of the Figure

FIG. 1 is a representative powder X-ray diffraction pattern of the Form I crystalline polymorph of Cefdinir.

FIG. 2 is a representative powder X-ray diffraction pattern of the Form II crystalline
30 polymorph of Cefdinir.

FIG. 3 is the infrared spectrum of the Form I crystalline polymorph of Cefdinir.

FIG. 4 is the infrared spectrum of the Form II crystalline polymorph of Cefdinir.

FIG. 5 is the TGA of the Form II crystalline polymorph of Cefdinir.

Summary of the Invention

35

The present invention describes a novel crystalline polymorphs of Cefdinir. For the sake of identification, this crystalline polymorph is designated as the Form II crystalline polymorph of Cefdinir.

40 In its principle embodiment the present invention describes a crystalline polymorph of Cefdinir with characteristic peaks in the powder X-ray diffraction pattern at values of two theta of $8.1 \pm 0.1^\circ$, $10.7 \pm 0.1^\circ$, $12.1 \pm 0.1^\circ$, $13.7 \pm 0.1^\circ$, $17.8 \pm 0.1^\circ$, $19.0 \pm 0.1^\circ$, $20.4 \pm 0.1^\circ$, $21.5 \pm 0.1^\circ$, $22.2 \pm 0.1^\circ$, $23.0 \pm 0.1^\circ$, $24.3 \pm 0.1^\circ$, and $25.5 \pm 0.1^\circ$.

In another embodiment the present invention describes a crystalline polymorph of Cefdinir prepared by a process comprising suspending crystalline Form I of Cefdinir
45 (preferably about 300 mg) in a solvent for a period of time (preferably about 1 to about 8 weeks) followed by isolating the desired polymorph. Preferably this process is conducted at about 20 °C to about 40 °C, most preferably at about 23 °C. Preferred solvents are water, ethanol, methanol, propanol, isopropanol, acetonitrile, formamide, N-methylpyrrolidinone, N,N-dimethylformamide, triethylamine, diisopropylethylamine, toluene, xylene, mesitylene,
50 ethyl acetate, isopropyl acetate, tetrahydrofuran, dioxane, diethyl ether, methyl tert-butyl ether, dichloromethane, chloroform, carbon tetrachloride, hexane, pentane, heptane, acetone, methyl ethyl ketone, dimethylsulfoxide, pyridine, nitromethane, and mixtures thereof. More preferred solvents are water, ethanol, acetonitrile, formamide, N-methylpyrrolidinone, triethylamine, toluene, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, hexane,
55 acetone, methyl ethyl ketone, dimethylsulfoxide, pyridine, nitromethane, 1:1 water/ethanol, 1:1 water/acetonitrile, and 1:1 water/acetone. A most preferred solvent is pyridine.

In another embodiment the present invention describes a process for the preparation of the crystalline polymorph of claim 1 comprising suspending Form I of Cefdinir in a solvent, then isolating the desired polymorph. Preferably this process is conducted at about
60 20 °C to about 40 °C, most preferably at about 23 °C. Preferred solvents are water, ethanol, methanol, propanol, isopropanol, acetonitrile, formamide, N-methylpyrrolidinone, N,N-dimethylformamide, triethylamine, diisopropylethylamine, toluene, xylene, mesitylene, ethyl acetate, isopropyl acetate, tetrahydrofuran, dioxane, diethyl ether, methyl tert-butyl ether, dichloromethane, chloroform, carbon tetrachloride, hexane, pentane, heptane, acetone, methyl
65 ethyl ketone, dimethylsulfoxide, pyridine, nitromethane, and mixtures thereof. More preferred solvents are water, ethanol, acetonitrile, formamide, N-methylpyrrolidinone, triethylamine, toluene, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, hexane, acetone, methyl ethyl ketone, dimethylsulfoxide, pyridine, nitromethane, 1:1 water/ethanol, 1:1 water/acetonitrile, and 1:1 water/acetone. A most preferred solvent is pyridine.

70 In another embodiment the present invention describes a pharmaceutical composition comprising crystal Form II of Cefdinir in combination with a pharmaceutically acceptable carrier.

Detailed Description of the Invention

75 Powder X-ray diffraction was performed using an XDS-2000 / X-ray diffractometer equipped with a 2 kW normal focus X-ray tube and a Peltier cooled germanium solid-state detector (Scintag Inc., Sunnyvale, CA). The data was processed using DMSNT software (version 1.37). The X-ray source was a copper filament operated at 45 kV and 40 mA. The alignment of the goniometer was checked daily using a Corundum standard. The sample was
80 placed in a thin layer onto a zero background plate, and continuously scanned at a rate of 2° two-theta per minute over a range of 2 to 40° two-theta.

Characteristic powder X-ray diffraction pattern peak positions are reported for polymorphs in terms of the angular positions (two theta) with an allowable variability of $\pm 0.1^\circ$. This allowable variability is specified by the U.S. Pharmacopeia, pages 1843-1884
85 (1995). The variability of $\pm 0.1^\circ$ is intended to be used when comparing two powder X-ray diffraction patterns. In practice, if a diffraction pattern peak from one pattern is assigned a range of angular positions (two theta) which is the measured peak position $\pm 0.1^\circ$ and if those ranges of peak positions overlap, then the two peaks are considered to have the same angular position (two theta). For example, if a diffraction pattern peak from one pattern is
90 determined to have a peak position of 5.2° , for comparison purposes the allowable variability allows the peak to be assigned a position in the range of $5.1^\circ - 5.3^\circ$. If a comparison peak from the other diffraction pattern is determined to have a peak position of 5.3° , for comparison purposes the allowable variability allows the peak to be assigned a position in the range of $5.2^\circ - 5.4^\circ$. Because there is overlap between the two ranges of peak positions (i.e.,
95 $5.1^\circ - 5.3^\circ$ and $5.2^\circ - 5.4^\circ$) the two peaks being compared are considered to have the same angular position (two theta).

Transmission infrared spectroscopy of the solids were obtained using a Fourier-transform infrared spectrometer (Nicolet Magna 750 FT-IR Spectrometer, Nicolet Instrument Corporation, Madison, WI) equipped with a Nicolet NIC-PLAN microscope. The
100 microscope had an MCT-A liquid nitrogen cooled detector. The sample was rolled on a 13mm x 1mm BaF₂ disc sample holder; 64 scans were collected at 4 cm⁻¹ resolution.

Thermogravimetric analysis was performed in TA Instruments TG2950 (TA Instruments, New Castle, DE). The samples were scanned at 10 °C/minute with a dry nitrogen purge at 60 mL/minute.

105 In accordance with methods of treatment and pharmaceutical compositions of the invention, the compounds can be administered alone or in combination with other agents. When using the compounds, the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed;

110 the age, body weight, general health, sex, and diet of the patient; the time of administration;
the route of administration; the rate of excretion of the compound employed; the duration of
treatment; and drugs used in combination with or coincidentally with the compound used. The
compounds can be administered orally, parenterally, intranasally, rectally, vaginally, or
topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or
115 combinations thereof. The term "parenteral" includes infusion as well as subcutaneous,
intravenous, intramuscular, and intrasternal injection.

Parenterally administered aqueous or oleaginous suspensions of the compounds can
be formulated with dispersing, wetting, or suspending agents. The injectable preparation can
also be an injectable solution or suspension in a diluent or solvent. Among the acceptable
120 diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides,
diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or
diglycerides.

The effect of parenterally administered compounds can be prolonged by slowing their
absorption. One way to slow the absorption of a particular compound is administering
125 injectable depot forms comprising suspensions of poorly soluble crystalline or otherwise
water-insoluble forms of the compound. The rate of absorption of the compound is
dependent on its rate of dissolution which, in turn, is dependent on its physical state. Another
way to slow absorption of a particular compound is administering injectable depot forms
comprising the compound as an oleaginous solution or suspension. Yet another way to slow
130 absorption of a particular compound is administering injectable depot forms comprising
microcapsule matrices of the compound trapped within liposomes, or biodegradable polymers
such as polylactide-polyglycolide, polyorthoesters or polyanhydrides. Depending on the ratio
of drug to polymer and the composition of the polymer, the rate of drug release can be
controlled.

135 Transdermal patches can also provide controlled delivery of the compounds. The rate
of absorption can be slowed by using rate controlling membranes or by trapping the
compound within a polymer matrix or gel. Conversely, absorption enhancers can be used to
increase absorption.

Solid dosage forms for oral administration include capsules, tablets, pills, powders,
140 and granules. In these solid dosage forms, the active compound can optionally comprise
excipients such as sucrose, lactose, starch, microcrystalline cellulose, mannitol, talc, silicon
dioxide, polyvinylpyrrolidone, sodium starch glycolate, magnesium stearate, etc. Capsules,
tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with
enteric coatings or other release-controlling coatings. Powders and sprays can also contain
145 excipients such as talc, silicon dioxide, sucrose, lactose, starch, or mixtures thereof. Sprays

can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes thereof.

Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents. Liquid dosage forms may also be contained within soft elastic capsules.

Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches. The compound is mixed, if necessary under sterile conditions, with a carrier and any needed preservatives or buffers. These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, talc and zinc oxide, or mixtures thereof. Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina. Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

The following examples will serve to further illustrate the preparation of the novel crystal forms. Form I of Cefdinir was prepared according to the procedure described in U.S. Patent Serial No. 4,935,507, issued June 19, 1990.

Example 1

Preparation of Novel Cefdinir Polymorph from Water

The solubility of Cefdinir Form I in water was determined. A suspension of Cefdinir Form I (300 mg in excess of the determined solubility) in 4 mL of water was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 2

Preparation of Novel Cefdinir Polymorph from Ethanol

185 The solubility of Cefdinir Form I in ethanol was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of ethanol was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between
190 the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If
195 the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 3

Preparation of Novel Cefdinir Polymorph from Acetonitrile

200 The solubility of Cefdinir Form I in acetonitrile was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of acetonitrile was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is
205 generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic
210 methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 4

Preparation of Novel Cefdinir Polymorph from Formamide

215 The solubility of Cefdinir Form I in formamide was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of formamide was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the

220 saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized
225 by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

230 Example 5

Preparation of Novel Cefdinir Polymorph from N-methylpyrrolidinone

The solubility of Cefdinir Form I in N-methylpyrrolidinone was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of N-
235 methylpyrrolidinone was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is
240 determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the
245 existence of a desolvated phase having a new crystal lattice.

Example 6

Preparation of Novel Cefdinir Polymorph from Triethylamine

The solubility of Cefdinir Form I in triethylamine was determined. A suspension of
250 Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of triethylamine was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is
255 examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized

by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 7

Preparation of Novel Cefdinir Polymorph from Toluene

The solubility of Cefdinir Form I in toluene was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of toluene was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 8

Preparation of Novel Cefdinir Polymorph from Ethyl Acetate

The solubility of Cefdinir Form I in ethyl acetate was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of ethyl acetate was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

295

Example 9

Preparation of Novel Cefdinir Polymorph from Tetrahydrofuran

The solubility of Cefdinir Form I in tetrahydrofuran was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of tetrahydrofuran was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

310

Example 10

Preparation of Novel Cefdinir Polymorph from Dioxane

The solubility of Cefdinir Form I in dioxane was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of dioxane was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

325

Example 11

Preparation of Novel Cefdinir Polymorph from Dichloromethane

The solubility of Cefdinir Form I in dichloromethane was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of dichloromethane was

330

allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 12

Preparation of Novel Cefdinir Polymorph from Hexane

The solubility of Cefdinir Form I in hexane was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of hexane was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 13

Preparation of Novel Cefdinir Polymorph from Acetone

The solubility of Cefdinir Form I in acetone was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of acetone was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has

been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice. /

Example 14

Preparation of Novel Cefdinir Polymorph from Methyl Ethyl Ketone

The solubility of Cefdinir Form I in methyl ethyl ketone was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of methyl ethyl ketone was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 15

Preparation of Novel Cefdinir Polymorph from Dimethylsulfoxide

The solubility of Cefdinir Form I in dimethylsulfoxide was determined. A suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of dimethylsulfoxide was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to

determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a
405 desolvated phase having a new crystal lattice.

Example 16

Preparation of Novel Cefdinir Polymorph from Pyridine

The solubility of Cefdinir Form I in pyridine was determined. A suspension of
410 Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of pyridine was allowed to stand
at room temperature. After 1 week, the solid from the suspension was separated and the
saturated solution was reserved. The powder X-ray diffraction pattern of the moist solid was
generated and the solid was returned to the reserved solution.

Example 17

Preparation of Novel Cefdinir Polymorph from Nitromethane

The solubility of Cefdinir Form I in nitromethane was determined. A suspension of
Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of nitromethane was allowed to
stand at room temperature. After 1 week, the solid from the suspension is separated and the
420 saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is
generated and the solid is returned to the reserved solution. If a difference is seen between
the newly generated diffraction pattern and that of the original Cefdinir the suspension is
examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has
been completely transformed into the new phase. At this time the new phase is characterized
425 by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic
methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If
the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the
stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated
phase having a new crystal lattice.

430

Example 18

Preparation of Novel Cefdinir Polymorph from 1:1 Water/Ethanol

The solubility of Cefdinir Form I in 1:1 water/ethanol was determined. A suspension
of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of 1:1 water/ethanol was
435 allowed to stand at room temperature. After 1 week, the solid from the suspension is
separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the
moist solid is generated and the solid is returned to the reserved solution. If a difference is
seen between the newly generated diffraction pattern and that of the original Cefdinir the
suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended
440 solid has been completely transformed into the new phase. At this time the new phase is

characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a
445 desolvated phase having a new crystal lattice.

Example 19

Preparation of Novel Cefdinir Polymorph from 1:1 Water/Acetonitrile

The solubility of Cefdinir Form I in 1:1 water/acetonitrile was determined. A
450 suspension of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of 1:1 water/acetonitrile was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is seen between the newly generated diffraction pattern and that of the original
455 Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a polymorph. If the new phase is a solvate, the desolvated phase is isolated in an
460 attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.

Example 20

Preparation of Novel Cefdinir Polymorph from 1:1 Water/Acetone

The solubility of Cefdinir Form I in 1:1 water/acetone was determined. A suspension
465 of Cefdinir Form I (300 mg in excess of the solubility) in 4 mL of 1:1 water/acetone was allowed to stand at room temperature. After 1 week, the solid from the suspension is separated and the saturated solution is reserved. The powder X-ray diffraction pattern of the moist solid is generated and the solid is returned to the reserved solution. If a difference is
470 seen between the newly generated diffraction pattern and that of the original Cefdinir the suspension is examined again at weeks 2, 4, and 8, or until it is determined that the suspended solid has been completely transformed into the new phase. At this time the new phase is characterized by powder X-ray diffraction, thermal methods (DSC, THA, HSM), and spectroscopic methods (mid IR, NIR) to determine whether the new phase is a solvate or a
475 polymorph. If the new phase is a solvate, the desolvated phase is isolated in an attempt to determine the stoichiometry of the solvate, the existence of isomorphs, and the existence of a desolvated phase having a new crystal lattice.